BRIC Expenditures Increasing at a Much Faster Pace than US
IMS Health
Clinical subject expenditures are sizable and represent an average of 5% of per-patient budget of later phase clinical trials. Relative subject reimbursement costs can play a large role in which region to select.
IMS Health maintains current data on relative costs of clinical subject reimbursements around the world in the GrantPlan database, which contains the clinical investigator grants for sponsor companies and CROs that conduct over three quarters of all commercial clinical trials.
Current analysis demonstrates the reimbursement per subject in these emerging geographies is growing more rapidly than in the more established US region. The United States has been averaging 8% annual expense increases and ~1% stipend increase from 2011-2013, while reimbursement costs in BRIC countries (Brazil, Russia, India, and China) are growing at two times those rates, with ~20% expense increase and 17% stipend increase. Russia is by far the highest increase. Even if BRIC countries are starting off on a lower base compared to the US, the rapid rise in cost in these regions warrant our careful consideration in the coming years.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
